3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
31
Neoplasms
8
Neoplasm Metastasis
8
Brain Neoplasms
5
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Glioma
4
Endometrial Neoplasms
4
Triple Negative Breast Neoplasms
3
Neoplasms by Site
3
Breast Diseases
3
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Meningioma
2
Liposarcoma
2
Head and Neck Neoplasms
2
Glioblastoma
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Kaposi
1
Sarcoma, Ewing
1
Sarcoma
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neurofibromatosis 1
1
Neoplasms, Squamous Cell
1
Neoplasm, Residual
1
Interventions
Fulvestrant
4
ribociclib
2
palbociclib
2
Irinotecan
2
Gemcitabine
2
venetoclax
1
tivozanib
1
serabelisib
1
sapanisertib
1
niraparib
1
lorlatinib
1
liposomal doxorubicin
1
inavolisib
1
exemestane
1
encorafenib
1
cemiplimab
1
binimetinib
1
abemaciclib
1
Taxes
1
Tamoxifen
1
STX-478
1
Paclitaxel
1
Metformin
1
Lomustine
1
Letrozole
1
Imlunestrant
1
Doxorubicin
1
Cetuximab
1
Carboplatin
1
CA-4948
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
abemaciclib
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled